Purapharm Corp Ltd operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Purapharm Corp Ltd with three other
pharmaceutical manufacturers in Asia:
Hwail Pharmaceutical Company Limited
of KOREA (SOUTH)
sales of 108.74 billion Korean Won [US$93.41 million]
Hatay Pharmaceutical JSC
(2.04 trillion Vietnamese Dong [US$88.02 million]
Ttk Healthcare Limited
based in INDIA
(6.28 billion Indian Rupees [US$85.39 million]
of which 34%
Purapharm Corp Ltd reported sales of HK$695.88 million (US$89.79 million)
December of 2019.
decrease of 6.7%
versus 2018, when the company's sales were HK$745.50 million.
Contributing to the drop in overall sales was the 12.1% decline
in China Ccmg, from HK$324.61 million to HK$285.22 million.
There were also decreases in sales in
Hong Kong Ccmg (down 5.9% to HK$161.57 million)
Chinese Healthcare Products (down 8.7% to HK$90.43 million)
However, these declines were partially offset by the increase in sales of
Clinics (up 0.6% to HK$96.41 million)
Plantation (up 14.8% to HK$62.24 million)